Potential Influence of Centrally Acting Herbal Drugs on Transporters at the Blood–Cerebrospinal Fluid Barrier and Blood–Brain Barrier

被引:0
作者
Lilian W. Kibathi
SoHyun Bae
Scott R. Penzak
Parag Kumar
机构
[1] National Institutes of Health (NIH),Clinical Pharmacokinetics Research Unit, Clinical Center Pharmacy Department
[2] University of Iowa College of Pharmacy,Department of Pharmacotherapy
[3] University of North Texas System,undefined
[4] College of Pharmacy,undefined
来源
European Journal of Drug Metabolism and Pharmacokinetics | 2018年 / 43卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Complementary and alternative medications (CAM) with known or suspected pharmacologic activity in the central nervous system (CNS) are common. These herbal preparations may cause clinically significant drug–drug interactions (DDIs) when coadministered with medications that act in the CNS. This can result in negative outcomes such as toxicity or loss of efficacy. Most drug interaction reports with CAM focus on cytochrome P450 (CYP) modulation. However, drug interactions between CAM and conventional medications may occur via mechanisms other than CYP inhibition or induction; in particular, modulation of drug transport proteins represents an important mechanism by which such interactions may occur. This article provides an updated review of transporter-mediated mechanisms by which herbal products may theoretically interact with centrally acting medications at the blood–brain barrier and blood–cerebrospinal fluid (CSF) barrier. Further research is required before the true clinical impact of interactions involving modulation of centrally located membrane transporters can be fully understood.
引用
收藏
页码:619 / 635
页数:16
相关论文
共 513 条
[41]  
Fricker G(2008)Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance Basic Clin Pharmacol Toxicol 102 466-779
[42]  
Bennett DA(2008)Coma from the health food store: interaction between kava and alprazolam Mol Nutr Food Res 52 772-805
[43]  
Phun L(2010)Kavapyrone enriched extract from Pharmacotherapy. 30 797-186
[44]  
Polk JF(2013) as modulator of the GABA binding site in different regions of rat brain Phytomed Int J Phytother Phytopharm. 20 178-599
[45]  
Voglino SA(2008)Inhibition of human cytochrome P450 activities by kava extract and kavalactones Curr Med Res Opin 24 591-758
[46]  
Zlotnik V(2005)Anti-inflammatory effects of essential oil in J Pharm Pharmacol 57 751-85
[47]  
Raffa RB(2012) L Eur J Pharm Sci Off J Eur Fed Pharm Sci. 46 79-735
[48]  
Wurglics M(2010)In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products Eur J Pharm Sci Off J Eur Fed Pharm Sci. 41 729-505
[49]  
Schubert-Zsilavecz M(2010)Gauging the clinical significance of P-glycoprotein-mediated herb–drug interactions: comparative effects of St. John’s wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics Biopharm Drug Dispos 31 495-238
[50]  
Moore LB(2002) significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects Clin Infect Dis Off Publ Infect Dis Soc Am. 34 234-1362